Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
about
Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous dosesIn vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridoneCefepimeCefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndromeSusceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.Prospective monitoring of cefepime in intensive care unit adult patientsSHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacaeThe evolving role of chemical synthesis in antibacterial drug discovery.Development and validation of a rapid turbidimetric assay to determine the potency of cefuroxime sodium in powder for dissolution for injectionPharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents.Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levelsEfficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporinEffects of age and gender on pharmacokinetics of cefepimeIn vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrumComparative activity of cefepime with several antimicrobials against aerobic Gram-negative and Gram-positive organisms isolated from patients across Canada in 1993.Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats.Open trial of cefepime (BMY 28142) for infections in hospitalized patients.High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.BMY 28100, a new oral cephalosporin.Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.Multiply resistant mutants of Enterobacter cloacae selected by beta-lactam antibioticsIn vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.Lack of pharmacokinetic interaction between cefepime and amikacin in humansPharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329.Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.
P2860
Q28251630-54B0EAB2-5143-41C1-83F9-ED930EEF7AC6Q28359405-75A9D317-0182-416D-878B-3FBBF4A08199Q29040262-5FA9FB04-5B91-4C32-9553-CA02023D9269Q33693985-C328B6E3-245C-4F97-A58A-BD236C3406F9Q33750327-F6EBD539-B05D-4E8B-AA07-1066FE506EFFQ33753762-B4FB8AD1-0C1D-4F11-81E9-5FEE2DFB27C3Q33919165-B2B8B07F-B294-4A6E-AA92-F254B8DDA127Q34073514-9AA05DFA-9FAA-40FE-9BDF-DD03CB859F0EQ34427652-92A40E9B-5598-476A-9275-E6690D783617Q34569147-FE0B9343-9A50-425A-906D-7ABEAF22FC1DQ34937147-FE736F27-A036-4277-83F8-6B11363551E1Q35013708-35BD9EB8-7FD0-4D1E-A1F9-1AD24C2710AAQ35278735-AFAFDAA4-3D58-4B52-A5E3-97B399FE8B36Q35326845-D0C7DC0B-84BC-4DF5-921B-21C898A8E57AQ35571357-F075E2D6-5FE4-402C-8FDA-27D0FF437D07Q35807617-4682C1DD-BE22-40C9-93A9-13B0618151D1Q35862379-DF2D3CD6-96D6-4F96-BCF6-50D5B3468D81Q35884688-9C035C56-4795-4300-869A-9B67779C87E1Q35893006-C577EC0D-85E2-404A-B240-3766E71DFF13Q36753528-C1759FCB-4394-431F-95E0-10680441469FQ36753861-D208BE92-E56B-4601-8C2D-0659FCB6B10FQ36757620-CB33466D-B8E5-4966-9BAA-13D4F76C878AQ36758208-D111C929-6924-4AFA-9EC7-92802B9E0A71Q39721085-8904AA99-2692-4EA0-A909-75B8E18B5CB9Q39779559-1211FC22-A379-4B1D-A9A7-DCC50EEC7EC7Q39815828-0F6226EA-3C7A-464A-B5C7-9369927700BCQ39816064-AB5A7D29-C6DB-48B0-B882-9216468DEF53Q39827457-864B3488-670F-4993-9306-3EC9C00FDA43Q39827644-FC0C88C5-6FDF-47F4-95BF-D420D4C98FA7Q39828216-DFDA3B6C-D0B4-4C91-BF0D-88FD0AAA1C7FQ39834931-A35A045F-B8B9-4DA4-899F-18E09706B4BCQ39865892-CD3494EA-5905-4E22-9503-620FA0123713Q39875827-3A1A446F-B6C7-4483-8A74-25D99318A6B0Q39879612-BF3760B5-79C8-43B1-8AE2-4226408701D3Q39879617-755555C2-F3D9-4097-B21E-2FAD0992D368Q39881805-ED3ED77B-16E9-454C-BAD5-3023638AD907Q40088008-B9AEF5C2-21AC-4B4B-8D08-3A35810E73F3Q40283567-BD0B82C2-C4C5-4FDB-8AC7-D481E4A791E5Q40346786-E193678C-B777-4D01-BEE5-9CDC117BA58FQ40445411-F0AAB251-81FE-49CA-B6F1-5559E33B0E9F
P2860
Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@en
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@nl
type
label
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@en
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@nl
prefLabel
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@en
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@nl
P2093
P2860
P356
P1476
Comparison of a new cephalospo ...... ctrum beta-lactam antibiotics.
@en
P2093
Chisholm DR
Kessler RE
Pursiano TA
P2860
P304
P356
10.1128/AAC.27.2.207
P407
P577
1985-02-01T00:00:00Z